Israeli Ministry of Health approves intravenous Remodulin
Posted: 01-11-2006 :

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. -- United Therapeutics Corporation (Nasdaq: UTHR) announced that the Drug Registration Department of the Israeli Ministry of Health has expanded the label of Remodulin(R) (treprostinil sodium) Injection to include intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders.

The Israeli approval represents the third national approval of intravenous Remodulin following United States Food and Drug Administration approval on November 24, 2004 and the Canadian Therapeutic Products Directorate approval on October 6, 2005. United Therapeutics has also submitted a marketing application for intravenous Remodulin in France, with filings in additional countries planned during 2006.

"We and our Israeli distribution partner, Pharmateam Marketing, are very pleased with this authorization to offer intravenous Remodulin to patients and physicians in Israel," said Martine Rothblatt, Ph.D., United Therapeutics Chairman and CEO. "Since 2002 the Israeli market has been an important trailblazer for United Therapeutics."

United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapeutic products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases.  www.unither.com